UPDATE 3- Eylea helps Regeneron smash profit estimates

UPDATE 3- Eylea helps Regeneron smash profit estimates


Regeneron Pharmaceuticals Inc's quarterly profit handsomely beat estimates on strong demand for its flagship Eylea drug, prompting the U.S. drugmaker to raise its full-year growth forecast for the eye treatment. Sales of Eylea, which is used to treat macular degeneration and other eye disorders that cause age-related vision loss, came in at $919 million and beat analysts' estimates, helped by higher demand as the U.S. population ages.



from Biotech News